STUDY ON CHANGES OF SOME CYTOKINES IN SYSTEMIC ERYTHRODERMIC PSORIASIS

Thị Nga Phạm1,, Văn Em Đặng2, Hữu Doanh Lê3
1 Vietnamese-Czechoslovak friendship hospital in Hai Phong
2 108 Military Central Hospital
3 National Hospital of Dermatology and Venereology

Main Article Content

Abstract

Objectives: Study on concentrations of IL-2, IL-4, IL-6, IL-8, IL-10, IL-17, TNF-α, INF-γ in generalized erythrodermic psoriasis at Central Institute of Dermatology. Patients and methods: A prospective, cross-sectional descriptive study with comparative control was conducted. 30 patients with erythrodermic psoriasis without contraindications to Methotrexate and 30 healthy subjects similar in age and sex. Results: Before treatment: The patient group had concentrations of IL-2 (32.16 ± 79.53), IL-4 (5.72 ± 10.81), IL-6 (66.28 ± 221.61), IL- 8 (355.84 ± 508.11), IL-10 (5.95±10.42), IL-17 (11.55±9.23), TNF-α (6.56 ± 14.60), INF-γ(11.55 ± 9.23) 9,23), higher than the control group with p < 0.0001. There wasn’t relevance between the levels of cytokines and disease age, age and sex. After treatment: The concentrations of IL-6, IL-8 and TNF-α were reduced compared with before treatment with p<0.001, p<0.01, p<0.05 (in order). Conclusion: Concentrations of IL-2, IL-4, IL-6, IL-8, IL-10, IL-17, TNF-α, INF-γ in RTIs patients before treatment were higher than in healthy subjects and there was no relationship, without a relevance between cytokine levels and sex, disease age and age. Post-treatment cytokine levels were still higher than in the healthy group. Particularly, the concentration of IL-6, IL-8, TNF-α after treatment decreased compared to before treatment.

Article Details

References

1. Hawilo A, Zaraa I, Benmously R, et al. (2011). Erythrodermie psoriasique: profil epidemio-clinique et therapeutique a propos de 60 cas. Tunis Med, 89(11), 841–847. French.
2. Li L-F, Sujan SA, Yang H, Wang W-H. (2005). Serum immunoglobulins in psoriatic erythroderma. Clin Exp Dermatol, 30(2), 125–127.
3. Rosenbach M, Hsu S, Korman NJ, et al. (2010). Treatment of erythrodermic psoriasis: from the medical board of the National Psoriasis Foundation. J Am Acad Dermatol, 62(4), 655–662.
4. Takahashi MDF, Castro LGM, Romiti R (2007). Infliximab, as sole or combined therapy, induces rapid clearing of erythrodermic psoriasis. British Journal of Dermatology, 157 (4): 828–831.
5. Viguier M, Pagès C, Aubin F, et al. (2012). Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study. Br J Dermatol, 167(2), 417–423.
6. Zhang P, Chen H, Duan Y, et al (2015). Analysis of Th1/Th2 response pattern for erythrodermic psoriasis. (2015). J Huazhong Univ Sci Technolog Med Sci, 34(4), 596–601.
7. Khaled A, Ben Hamida M, Zeglaoui F, et al. (2012). Traitement du psoriasis par méthotrexate à l’ère des biothérapies: étude chez 21 patients tunisiens, 67(1), 49–52.